Lipigon Pharmaceuticals AB (publ) (LPGO.ST)

SEK 0.17

(-4.69%)

Market Cap (In SEK)

22.62 Million

Revenue (In SEK)

16.4 Million

Net Income (In SEK)

-12.12 Million

Avg. Volume

423 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.112-0.598
PE
-
EPS
-
Beta Value
0.578
ISIN
SE0015382072
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Stefan K. Nilsson
Employee Count
-
Website
https://www.lipigon.se
Ipo Date
2021-03-01
Details
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.